Comparative effectiveness and safety of GATT with or without ABiC in patients with open-angle glaucoma

GATT联合或不联合ABiC治疗开角型青光眼患者的疗效和安全性比较

阅读:1

Abstract

BACKGROUND: This is the first comprehensive comparison between gonioscopy-assisted transluminal trabeculotomy (GATT) and GATT combined with ab interno canaloplasty (ABiC) in patients with OAG. PURPOSE: The purpose of this study was to compare the efficacy and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) combined with ab interno canaloplasty (ABiC) with those of GATT alone in patients with open-angle glaucoma (OAG). DESIGN: This was a retrospective, comparative case series. PARTICIPANTS: Patients with primary open angle glaucoma who underwent GATT (27 eyes in Group 1) or GATT + ABiC (26 eyes in Group 2) were included. METHODS: Outcomes including intraocular pressure (IOP), glaucoma medications, and surgical complications were analyzed. MAIN OUTCOME MEASURES: Surgical success was defined in terms of IOP and medication use as follows: (1) a preoperative IOP > 21 mmHg and a postoperative IOP ≤ 21 mmHg with at least a 20% reduction from baseline with (qualified success) or without (complete success) glaucoma medications or (2) a preoperative IOP < 21 mmHg while taking 3 or more glaucoma medications and a postoperative IOP ≤ 21 mmHg with a reduction of more than two medications (qualified success) or with no medications (complete success). RESULTS: At 12 months, the mean IOP was 14.8 ± 2.2 mmHg in Group 1 and 16.6 ± 2.3 mmHg in Group 2 (p = 0.008). The number of medications was 0.6 ± 1.0 in Group 1 and 0.9 ± 1.3 in Group 2 (p = 0.334). At 24 months, the mean IOP was 15.3 ± 2.0 mmHg in Group 1 and 15.5 ± 2.4 mmHg in Group 2 (p = 0.676). The number of medications was 0.5 ± 0.9 in Group 1 and 0.9 ± 1.1 in Group 2 (p = 0.197). The complete success rates were 63.0% in Group 1 and 50.0% in Group 2 (p = 0.16), and the qualified success rates were 81.5% in Group 1 and 76.9% in Group 2 (p = 0.51). CONCLUSION: The GATT procedure, with or without ABiC, is safe and effective in decreasing the IOP and the number of antiglaucoma medications used.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。